Strategies to optimize the validity of disease models in the drug discovery process.

Models of human diseases are necessary for experimental research into the biological basis of disease and for the development of treatments. They have an enormous impact upon the success of biomedical research. However, in spite of this, a consistent system for evaluating, expressing and comparing the clinical validity of disease models is not available. The purpose of this paper is, therefore, to provide a theoretical discussion of the concepts behind disease models and to develop a terminology and a framework to analyze and express the clinical validity of disease models.

[1]  W. Bunney,et al.  Animal model of depression. I. Review of evidence: implications for research. , 1969, Archives of general psychiatry.

[2]  B. Reisberg,et al.  Measuring cognition in advanced Alzheimer's disease for clinical trials. , 2002, Journal of neural transmission. Supplementum.

[3]  P. Behl,et al.  Progress in Clinical Neurosciences: Cognitive Markers of Progression in Alzheimer's Disease , 2005, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[4]  Richard Muscat,et al.  Chronic mild stress-induced anhedonia: A realistic animal model of depression , 1992, Neuroscience & Biobehavioral Reviews.

[5]  K. Hope,et al.  The Quality of Life in Alzheimer's Disease Scale: direct assessment of people with cognitive impairment. , 2004, Journal of clinical nursing.

[6]  P. Riederer,et al.  Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings , 2004, Neurodegenerative Diseases.

[7]  J. Hardy,et al.  Genome-wide analysis of the parkinsonism-dementia complex of Guam. , 2004, Archives of neurology.

[8]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[9]  M. Weiner,et al.  Molecular biomarkers in drug development. , 2004, Drug discovery today.

[10]  F. Barone,et al.  Pharmacological interventions for stroke: failures and future , 2002, Expert opinion on investigational drugs.

[11]  F. Sams-Dodd.  Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity , 1999, Reviews in the neurosciences.

[12]  C. Sergi,et al.  Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications , 2005 .

[13]  F. Sams-Dodd.  A Test of the Predictive Validity of Animal Models of Schizophrenia Based on Phencyclidine and D-Amphetamine , 1998, Neuropsychopharmacology.

[14]  N. Greig,et al.  The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. , 2005, Life sciences.

[15]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[16]  David L. Braff,et al.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia , 2004, Psychopharmacology.

[17]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[18]  Philip D. Harvey,et al.  Cognition in schizophrenia: impairments, determinants, and functional importance. , 2005, The Psychiatric clinics of North America.

[19]  Qian Sun,et al.  β-Amyloid secretases and β-amyloid degrading enzyme expression in lens , 2003 .

[20]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[21]  M. Véniant,et al.  Leptin: from animals to humans. , 2003, Current pharmaceutical design.

[22]  E. Israel,et al.  How pharmacogenomics will play a role in the management of asthma. , 2005, American journal of respiratory and critical care medicine.

[23]  Edvard I Moser,et al.  Spatial learning with unilateral and bilateral hippocampal networks , 2005, The European journal of neuroscience.

[24]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[25]  Richard J Smeyne,et al.  The MPTP model of Parkinson's disease. , 2005, Brain research. Molecular brain research.

[26]  Porsolt Rd.  Animal model of depression. , 1979 .

[27]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[28]  R. Swerdlow,et al.  Pathogenesis of Alzheimer’s disease , 2007, Clinical interventions in aging.

[29]  D. McHale,et al.  Pharmacogenomics and the Drug Discovery Pipeline , 2005 .

[30]  Qian Sun,et al.  Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens. , 2003, Molecular vision.

[31]  E. Goldberg,et al.  Neuropsychologic assessment of frontal lobe dysfunction. , 2005, The Psychiatric clinics of North America.

[32]  P. Bossuyt,et al.  Development and validation of methods for assessing the quality of diagnostic accuracy studies. , 2004, Health technology assessment.

[33]  Paul Alan Cox,et al.  A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Jenner.  The MPTP-treated primate as a model of motor complications in PD , 2003, Neurology.

[35]  G. Boog.  Obstetrical complications and subsequent schizophrenia in adolescent and young adult offsprings: is there a relationship? , 2004, European journal of obstetrics, gynecology, and reproductive biology.